Gambogic acid suppresses nasopharyngeal carcinoma via rewiring molecular network of cancer malignancy and immunosurveillance
Nasopharyngeal carcinoma (NPC) is a malignant tumor highly prevalent in Southeast Asia. The distant metastasis and disease recurrence are still unsolved clinical problems. In recent years, traditional Chinese medicine (TCM) monomers have become significantly attractive due to their advantages. Using high throughput drug sensitivity screening, we identified gambogic acid (GA) as a common TCM monomer displaying multiple anti-NPC effects. GA could effectively inhibit the proliferation of low differentiated cells and highly metastatic cells in NPC via inducing apoptosis and G2/M cell cycle arrest. In addition, GA obviously repressed the abilities of cell clone, migration, invasion, angiogenesis and represented satisfied synergistic effects combined with chemotherapy. Importantly, we found the elevated immune checkpoint CD47 stimulated after chemotherapy was dramatically impaired by GA treatment. Mechanically, the network pharmacology analyses unraveled that the oncogenic signaling pathways including STATs were rewired by GA treatment. Taken together, our study reveals a molecular basis and provides a rationale for GA application as the treatment regime in NPC therapy in future..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Biomedicine & Pharmacotherapy - 150(2022), Seite 113012- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tao Ren [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Cancer repression |
|---|
| doi: |
10.1016/j.biopha.2022.113012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ022170081 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ022170081 | ||
| 003 | DE-627 | ||
| 005 | 20230307054022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2022.113012 |2 doi | |
| 035 | |a (DE-627)DOAJ022170081 | ||
| 035 | |a (DE-599)DOAJ27b6e0a7cd6f411ebb21bd873508e99f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Tao Ren |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gambogic acid suppresses nasopharyngeal carcinoma via rewiring molecular network of cancer malignancy and immunosurveillance |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Nasopharyngeal carcinoma (NPC) is a malignant tumor highly prevalent in Southeast Asia. The distant metastasis and disease recurrence are still unsolved clinical problems. In recent years, traditional Chinese medicine (TCM) monomers have become significantly attractive due to their advantages. Using high throughput drug sensitivity screening, we identified gambogic acid (GA) as a common TCM monomer displaying multiple anti-NPC effects. GA could effectively inhibit the proliferation of low differentiated cells and highly metastatic cells in NPC via inducing apoptosis and G2/M cell cycle arrest. In addition, GA obviously repressed the abilities of cell clone, migration, invasion, angiogenesis and represented satisfied synergistic effects combined with chemotherapy. Importantly, we found the elevated immune checkpoint CD47 stimulated after chemotherapy was dramatically impaired by GA treatment. Mechanically, the network pharmacology analyses unraveled that the oncogenic signaling pathways including STATs were rewired by GA treatment. Taken together, our study reveals a molecular basis and provides a rationale for GA application as the treatment regime in NPC therapy in future. | ||
| 650 | 4 | |a Gambogic acid | |
| 650 | 4 | |a Nasopharyngeal carcinoma | |
| 650 | 4 | |a Cancer repression | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Immunotherapy | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Xian-Yu Bai |e verfasserin |4 aut | |
| 700 | 0 | |a Meng-Zhe Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Ning Xu |e verfasserin |4 aut | |
| 700 | 0 | |a Xing-Zhe Guo |e verfasserin |4 aut | |
| 700 | 0 | |a Liu-Jie Qin |e verfasserin |4 aut | |
| 700 | 0 | |a Zhi-Lin Huang |e verfasserin |4 aut | |
| 700 | 0 | |a Qiong-Yao Zhong |e verfasserin |4 aut | |
| 700 | 0 | |a Yuan-Jiao Huang |e verfasserin |4 aut | |
| 700 | 0 | |a Wen-Zhen Lin |e verfasserin |4 aut | |
| 700 | 0 | |a Ai-Jun Jiao |e verfasserin |4 aut | |
| 700 | 0 | |a Bei-Bei Zhang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Biomedicine & Pharmacotherapy |d Elsevier, 2021 |g 150(2022), Seite 113012- |w (DE-627)DOAJ078596181 |x 19506007 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2022 |g pages:113012- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.biopha.2022.113012 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/27b6e0a7cd6f411ebb21bd873508e99f |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0753332222004012 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0753-3322 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2022 |h 113012- | ||